These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31558911)

  • 21. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Cannabidiol on Human Brain Function: A Systematic Review.
    Batalla A; Bos J; Postma A; Bossong MG
    Front Pharmacol; 2020; 11():618184. PubMed ID: 33551817
    [No Abstract]   [Full Text] [Related]  

  • 23. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
    Zlebnik NE; Cheer JF
    Annu Rev Neurosci; 2016 Jul; 39():1-17. PubMed ID: 27023732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Cannabidiol on Psychiatric and Medical Conditions.
    Oberbarnscheidt T; Miller NS
    J Clin Med Res; 2020 Jul; 12(7):393-403. PubMed ID: 32655732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Cannabidiol in Treating Psychiatric Disorders: A Systematic Review.
    N Pavel A; Paun R; P Matei V
    Psychiatry Clin Psychopharmacol; 2021 Jun; 31(2):226-232. PubMed ID: 38765233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular and Cellular Mechanisms of Action of Cannabidiol.
    Martinez Naya N; Kelly J; Corna G; Golino M; Abbate A; Toldo S
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research.
    Melas PA; Scherma M; Fratta W; Cifani C; Fadda P
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidences for the Anti-panic Actions of Cannabidiol.
    Soares VP; Campos AC
    Curr Neuropharmacol; 2017; 15(2):291-299. PubMed ID: 27157263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A validated method for the simultaneous quantification of cannabidiol, Δ
    Kevin RC; Vogel R; Doohan P; Berger M; Amminger GP; McGregor IS
    Drug Test Anal; 2021 Mar; 13(3):614-627. PubMed ID: 33095968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabidiol and substance use disorder: Dream or reality.
    Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
    Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of cannabidiol in anxiety and anxiety-related disorders.
    Skelley JW; Deas CM; Curren Z; Ennis J
    J Am Pharm Assoc (2003); 2020; 60(1):253-261. PubMed ID: 31866386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder.
    Hua DY; Hindocha C; Baio G; Lees R; Shaban N; Morgan CJ; Mofeez A; Curran HV; Freeman TP
    Transl Psychiatry; 2023 Apr; 13(1):131. PubMed ID: 37085531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
    Gonzalez-Cuevas G; Martin-Fardon R; Kerr TM; Stouffer DG; Parsons LH; Hammell DC; Banks SL; Stinchcomb AL; Weiss F
    Neuropsychopharmacology; 2018 Sep; 43(10):2036-2045. PubMed ID: 29686308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.
    Navarrete F; García-Gutiérrez MS; Gasparyan A; Austrich-Olivares A; Manzanares J
    Front Pharmacol; 2021; 12():626010. PubMed ID: 34093179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol in the context of substance use disorder treatment: A systematic review.
    Paulus V; Billieux J; Benyamina A; Karila L
    Addict Behav; 2022 Sep; 132():107360. PubMed ID: 35580370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current trends on cannabidiol delivery systems: where are we and where are we going?
    Ramalho ÍMM; Pereira DT; Galvão GBL; Freire DT; Amaral-Machado L; Alencar ÉDN; Egito ESTD
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1577-1587. PubMed ID: 34253133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial.
    Dahlgren MK; Lambros AM; Smith RT; Sagar KA; El-Abboud C; Gruber SA
    Commun Med (Lond); 2022 Nov; 2(1):139. PubMed ID: 36352103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics.
    Buchtova T; Lukac D; Skrott Z; Chroma K; Bartek J; Mistrik M
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.